No Data
No Data
Eli Lilly Weight Loss Drug Approved in China
Eli Lilly, Novo Extend Muti-day Decline in Rare Selloff
Shares of weight loss drugmakers Eli Lilly (NYSE:LLY) and Novo Nordisk (NVO) extended a multi-day decline on Thursday, losing billions of dollars in market capitalization for two of the world’s biggest companies.
Novo Nordisk, Eli Lilly Fall on Data From Roche's Weight-loss Pill
Eli Lilly's GLP-1 Impact on ResMed Is Overblown: Barron's
Novo's Ozempic Linked to Improved Brain Health: Study
PepsiCo CEO: GLP-1 Drugs Are 'Not Impacting Us'
No Data